Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients

MeSH terms

• Disease-Free Survival
• Exome*
• Female
• High-Throughput Nucleotide Sequencing
• Humans
• Imatinib Mesylate / administration & dosage*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / mortality
• Male
• Middle Aged
• Mutation*
• Survival Rate